138 related articles for article (PubMed ID: 37907709)
1. Body mass index is a good predictor of metabolic abnormalities in polycystic ovary syndrome.
Fruzzetti F; Fidecicchi T; Benelli E; Baldari F; Tonacchera M
J Endocrinol Invest; 2024 Apr; 47(4):927-936. PubMed ID: 37907709
[TBL] [Abstract][Full Text] [Related]
2. [Clinical features, hormonal profile, and metabolic abnormalities of obese women with obese polycystic ovary syndrome].
Li X; Lin JF
Zhonghua Yi Xue Za Zhi; 2005 Dec; 85(46):3266-71. PubMed ID: 16409817
[TBL] [Abstract][Full Text] [Related]
3. [Exploration of the classification of polycystic ovarian syndrome].
Lin JF; Li X; Zhu MW
Zhonghua Fu Chan Ke Za Zhi; 2006 Oct; 41(10):684-8. PubMed ID: 17199924
[TBL] [Abstract][Full Text] [Related]
4. The Visceral Adiposity Index (VAI) and Lipid Accumulation Product (LAP) Are Predictors of Insulin Resistance and Hyperandrogenaemia in Obesity/Overweight Women with Polycystic Ovary Syndrome.
Wang H; Cao H; Cao J; Zhang L
Biomed Res Int; 2023; 2023():1508675. PubMed ID: 36814799
[TBL] [Abstract][Full Text] [Related]
5. Obesity contributes to telomere shortening in polycystic ovary syndrome.
Kogure GS; Verruma CG; Santana BA; Calado RT; Ferriani RA; Furtado CLM; Dos Reis RM
Reprod Sci; 2024 Jun; 31(6):1601-1609. PubMed ID: 38393627
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of the Efficacy of Sex Hormone-Binding Globulin in Insulin Resistance Assessment Based on HOMA-IR in Patients with PCOS.
Chen F; Liao Y; Chen M; Yin H; Chen G; Huang Q; Chen L; Yang X; Zhang W; Wang P; Yin G
Reprod Sci; 2021 Sep; 28(9):2504-2513. PubMed ID: 33721297
[TBL] [Abstract][Full Text] [Related]
7. Establishing the cut off values of androgen markers in the assessment of polycystic ovarian syndrome.
Nadaraja RND; Sthaneshwar P; Razali N
Malays J Pathol; 2018 Apr; 40(1):33-39. PubMed ID: 29704382
[TBL] [Abstract][Full Text] [Related]
8. Serum uric acid/creatinine ratio and free androgen index are synergistically associated with increased risk of polycystic ovary syndrome in obese women.
El-Eshmawy MM; Ibrahim A; Bahriz R; Shams-Eldin N; Mahsoub N
BMC Endocr Disord; 2022 Dec; 22(1):315. PubMed ID: 36514085
[TBL] [Abstract][Full Text] [Related]
9. Association of MEP1A gene variants with insulin metabolism in central European women with polycystic ovary syndrome.
Lam UD; Lerchbaum E; Schweighofer N; Trummer O; Eberhard K; Genser B; Pieber TR; Obermayer-Pietsch B
Gene; 2014 Mar; 537(2):245-52. PubMed ID: 24388959
[TBL] [Abstract][Full Text] [Related]
10. Influence of body mass index on measured and calculated androgen parameters in adult women with Hirsutism and PCOS.
Cupisti S; Dittrich R; Binder H; Kajaia N; Hoffmann I; Maltaris T; Beckmann MW; Mueller A
Exp Clin Endocrinol Diabetes; 2007 Jun; 115(6):380-6. PubMed ID: 17701884
[TBL] [Abstract][Full Text] [Related]
11. Controlled attenuation parameters to assess liver steatosis in obese patients with polycystic ovary syndrome.
Wang D; Nan N; Bing H; He B
Front Endocrinol (Lausanne); 2023; 14():1241734. PubMed ID: 37720537
[TBL] [Abstract][Full Text] [Related]
12. Effect of aging on clinical features and metabolic complications of women with polycystic ovary syndrome.
Falcetta P; Benelli E; Molinaro A; Di Cosmo C; Bagattini B; Del Ghianda S; Salvetti G; Fiore E; Pucci E; Fruzzetti F; Tonacchera M
J Endocrinol Invest; 2021 Dec; 44(12):2725-2733. PubMed ID: 34089497
[TBL] [Abstract][Full Text] [Related]
13. Polycystic ovary syndrome patients with high BMI tend to have functional disorders of androgen excess: a prospective study.
Yuan C; Liu X; Mao Y; Diao F; Cui Y; Liu J
J Biomed Res; 2016 May; 30(3):197-202. PubMed ID: 27526961
[TBL] [Abstract][Full Text] [Related]
14. Adrenal hyperandrogenism does not deteriorate insulin resistance and lipid profile in women with PCOS.
Paschou SA; Palioura E; Ioannidis D; Anagnostis P; Panagiotakou A; Loi V; Karageorgos G; Goulis DG; Vryonidou A
Endocr Connect; 2017 Nov; 6(8):601-606. PubMed ID: 28912337
[TBL] [Abstract][Full Text] [Related]
15. An inverse association between serum soluble receptor of advanced glycation end products and hyperandrogenism and potential implication in polycystic ovary syndrome patients.
Liao Y; Huang R; Sun Y; Yue J; Zheng J; Wang L; Tao T; Ma J; Li S; Liu W
Reprod Biol Endocrinol; 2017 Jan; 15(1):9. PubMed ID: 28125989
[TBL] [Abstract][Full Text] [Related]
16. Body mass index and ovarian function are associated with endocrine and metabolic abnormalities in women with hyperandrogenic syndrome.
Cupisti S; Kajaia N; Dittrich R; Duezenli H; W Beckmann M; Mueller A
Eur J Endocrinol; 2008 May; 158(5):711-9. PubMed ID: 18426831
[TBL] [Abstract][Full Text] [Related]
17. Serum total L-carnitine levels in non-obese women with polycystic ovary syndrome.
Fenkci SM; Fenkci V; Oztekin O; Rota S; Karagenc N
Hum Reprod; 2008 Jul; 23(7):1602-6. PubMed ID: 18378560
[TBL] [Abstract][Full Text] [Related]
18. Follistatin and activins in polycystic ovary syndrome: relationship to metabolic and hormonal markers.
Teede H; Ng S; Hedger M; Moran L
Metabolism; 2013 Oct; 62(10):1394-400. PubMed ID: 23768911
[TBL] [Abstract][Full Text] [Related]
19. The association of body mass index and biochemical hyperandrogenaemia in women with and without polycystic ovary syndrome.
Yasmin E; Balen AH; Barth JH
Eur J Obstet Gynecol Reprod Biol; 2013 Feb; 166(2):173-7. PubMed ID: 23102586
[TBL] [Abstract][Full Text] [Related]
20. White blood cells levels and PCOS: direct and indirect relationship with obesity and insulin resistance, but not with hyperandogenemia.
Papalou O; Livadas S; Karachalios A; Tolia N; Kokkoris P; Tripolitakis K; Diamanti-Kandarakis E
Hormones (Athens); 2015; 14(1):91-100. PubMed ID: 25553762
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
